- Home
- TEI vs RIGL Comparison
TEI vs RIGL Comparison
Compare TEI & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TEI | RIGL |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.5M | 537.6M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | TEI | RIGL |
|---|---|---|
| Price | $6.40 | $44.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.20 |
| AVG Volume (30 Days) | 142.4K | ★ 506.3K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | N/A | ★ 6.20 |
| Revenue | N/A | ★ $282,076,000.00 |
| Revenue This Year | N/A | $65.53 |
| Revenue Next Year | N/A | $0.22 |
| P/E Ratio | ★ N/A | $7.10 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $4.35 | $15.50 |
| 52 Week High | $5.39 | $52.24 |
Technical Indicators
Market Signals| Indicator | TEI | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 53.60 |
| Support Level | $6.23 | $40.52 |
| Resistance Level | $6.43 | $44.85 |
| Average True Range (ATR) | 0.08 | 2.33 |
| MACD | -0.02 | -0.27 |
| Stochastic Oscillator | 34.04 | 51.26 |
Price Performance
Historical ComparisonAbout TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.